Table 2. Summary by dataset of the prevalence and distribution of the genetic markers of resistance and resistance phenotypes tested.
| Variant | Genetic | Phenotypic | ||||
|---|---|---|---|---|---|---|
| RplD G70D | 23S rRNA C2611T (2–4 alleles) | penA XXXIV | CRO-RS (≥0.12 μg/mL) | CFX-R (>0.25 μg/mL) | ||
| Drug | AZM (Grad et al., 2016) | AZM (Lk et al., 2002) | ESCs (Grad et al., 2014) | N/A | N/A | |
| Prevalence of variant in dataset | 1 | 10.04%* | 0.11% | 5.25% | 1.47% | 0.11% |
| 2 | 1.14% | 1.24% | 1.69% | 0% | 0% | |
| 3 | 2.47% | 0.95% | 15.68%* | 1.04% | 0.76% | |
| 4 | 11.07%* | 1.23% | 0.41% | 6.56% | 8.20% | |
| 5 | 0.75% | 0.50% | 2.26% | 0.25% | 0% | |
| Phylogenetic D statistic for variant in dataset | 1 | −0.18 | 17.50 | −0.29 | N/A | N/A |
| 2 | −0.10 | 0.46 | −0.24 | N/A | N/A | |
| 3 | 0.05 | 0.30 | −0.20 | N/A | N/A | |
| 4 | −0.16 | 1.83 | 1.81 | N/A | N/A | |
| 5 | 0.83 | 1.12 | −0.15 | N/A | N/A | |
*Given the >10% prevalence of RplD G70D in datasets 1 and 4 and penA XXXIV in dataset 3, these variants were excluded from sampling simulations.
AZM, azithromycin; ESC, extended-spectrum cephalosporin; CRO-RS, ceftriaxone reduced susceptibility; CFX-R, cefixime resistance.